ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged – Hagens Berman

ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged – Hagens Berman GlobeNewswire November 10, 2025 SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class […]

U.S. Virgin Islands Unveils Updated Schedule and Star-Studded Lineup for 2025-2026 Crucian Christmas Festival Village

Featuring Kes the Band, Voice, Pumpa, Romain Virgo, Adam O, Morgan Heritage, and D'Yani, the Crucian Christmas Festival Village celebrates the rich diversity of Caribbean culture. The U.S. Virgin Islands Department of Tourism, in collaboration with the Division of Festivals, announces the updated schedule and Village lineup for the 2025-2026 Crucian Christmas Festival. Set to

James Hardie Industries (JHX) Lawsuit Alleges Securities Fraud Over Inventory Misstatements – Hagens Berman

(NYSE:JHX), SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — A class-action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX), the dominant producer of fiber cement building materials in the U.S., alleging the company committed securities fraud by misleading investors about inventory levels and customer demand in its crucial North American segment. Hagens

James Hardie Industries (JHX) Lawsuit Alleges Securities Fraud Over Inventory Misstatements – Hagens Berman

James Hardie Industries (JHX) Lawsuit Alleges Securities Fraud Over Inventory Misstatements – Hagens Berman JHX Investors with Losses Encouraged to Contact the Firm GlobeNewswire November 10, 2025 SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — A class-action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX), the dominant producer of fiber cement building

Minister Hodgson and Secretary of State Fuhr highlight budget investments in Canada’s forest sector

Canada faces a rapidly changing and increasingly uncertain world. The ruled-based international order and the trading system that powered Canada's prosperity for decades are being reshaped – hurting companies, displacing workers and causing major disruption and upheaval for Canadians. Today, the Honourable Tim Hodgson, Minister of Energy and Natural Resources, and the Honourable Stephen Fuhr,

Synopsys, Inc. (SNPS) Faces Securities Class Action Amid Q325 Results Revealing IP Business Problems – Hagens Berman

(NASDAQ:SNPS), SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — A securities fraud class action, styled Kim v. Synopsys, Inc., et al., No. 26-:cv-09410 (N.D. Cal.) has been filed and seeks to represent investors who purchased or otherwise acquired Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025. The lawsuit was filed

Synopsys, Inc. (SNPS) Faces Securities Class Action Amid Q325 Results Revealing IP Business Problems – Hagens Berman

Synopsys, Inc. (SNPS) Faces Securities Class Action Amid Q325 Results Revealing IP Business Problems – Hagens Berman GlobeNewswire November 10, 2025 SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — A securities fraud class action, styled Kim v. Synopsys, Inc., et al., No. 26-:cv-09410 (N.D. Cal.) has been filed and seeks to represent investors who purchased

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

(NasdaqGM:NTLA), One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baseline Longer-term safety data consistent with previously reported Phase 1 data CAMBRIDGE, Mass.,

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy GlobeNewswire November 10, 2025 One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of

Matter 1.4 Elevates the Linkind Smart Bulb Experience

Linkind is upgrading its range of Matter-enabled smart bulbs with Matter 1.4-the latest version of the industry-unifying smart home protocol. This update delivers meaningful improvements in speed, stability, and ecosystem integration, making your Linkind smart bulbs simpler to pair, easier to use, and more powerful than ever. Among the benefits of upgrading to Matter 1.4

Scroll to Top